Bayer AG's new ophthalmic Eylea (aflibercept injection) has had a successful launch in Japan, partly because of the selection of the right local co-promoting partner, Santen Pharmaceutical Co. Ltd., and the priority given by both companies to preparing for the launch, said Wolfgang Plischke, acting chairman of Bayer's health care division, during the company's first quarter analyst's call April 25.
Plischke took over as temporary chairman of Bayer Healthcare on March 1, after Joerg Reinhardt was appointed chairman of Switzerland’s Novartis AG Also see "Bayer’s Reinhardt Returning To...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?